By Market & Region

SHERIDAN, WYOMING - December 2, 2025 - Roche has secured FDA 510(k) clearance with a CLIA waiver and CE IVDR certification for its first point-of-care test to diagnose Bordetella infections, providing primary care and emergency clinicians with PCR-accurate results in just 15 minutes to help control whooping cough and related diseases.

Fast, PCR-accurate diagnosis at the point of care

Running on the cobas® liat system, Roche's new assay delivers lab-quality PCR results in GP offices and emergency rooms within a standard consultation. The 15-minute turnaround allows physicians to move from suspicion to definitive diagnosis immediately, supporting timely antibiotic prescribing that can prevent severe complications and reduce onward transmission.

SHERIDAN, WYOMING - December 2, 2025 - Roche has reported landmark Phase III results for its oral selective estrogen receptor degrader (SERD) giredestrant, positioning the candidate as a potential new standard of care in early-stage ER-positive, HER2-negative breast cancer after a pivotal trial showed superior invasive disease-free survival versus standard endocrine therapy.

First oral SERD to show superior invasive disease-free survival

The Phase III lidERA Breast Cancer study evaluated adjuvant giredestrant against standard-of-care endocrine monotherapy in more than 4,100 patients with medium- or high-risk stage I-III ER-positive, HER2-negative early breast cancer. At a pre-planned interim analysis, the trial met its primary endpoint: giredestrant delivered a statistically significant and clinically meaningful improvement in invasive disease-free survival compared with standard endocrine therapy.

SHERIDAN, WYOMING - December 2, 2025 - Royal Philips is expanding commercial availability of its LumiGuide 3D Device Guidance solution across Europe and the United States, positioning its real-time, AI-enabled, light-based navigation technology as a new benchmark for radiation-free image-guided therapy in complex endovascular procedures.

Real-time 3D navigation without continuous X-ray

SHERIDAN, WYOMING - December 2, 2025 - Roche is re-entering the frontline of Alzheimer's disease drug development, after new Phase I/II data showed its next-generation antibody trontinemab cleared amyloid plaques below the threshold of positivity in the vast majority of treated patients while keeping key safety signals under tight control.

Early Brainshuttle data show deep amyloid clearance

In the ongoing Brainshuttle AD Phase I/II study, 92% of patients treated with trontinemab achieved amyloid levels below 24 centiloids, the PET scan threshold commonly used to define amyloid positivity. The data, presented at the 2025 Clinical Trials on Alzheimer's Disease (CTAD) meeting, mark one of the strongest plaque-clearing signals yet seen in a mid-stage program.

SHERIDAN, WYOMING - December 2, 2025 - A leaked memo from FDA vaccine chief Vinay Prasad alleging that COVID-19 vaccines caused the deaths of 10 children has triggered a sharp backlash from scientific experts and investors, underscoring deep tensions inside U.S. vaccine regulation and adding fresh volatility for mRNA players Moderna and BioNTech.

An internal memo with external market consequences

In a six-page document titled "Deaths in children due to COVID-19 vaccines and CBER's path forward," Center for Biologics Evaluation and Research head Vinay Prasad claimed that an internal investigation had identified 10 child deaths "linked" to COVID-19 vaccination, based on reports in the Vaccine Adverse Events Reporting System (VAERS). The memo, published by The Washington Post, did not provide specific data, case details or manufacturer names.

SHERIDAN, WYOMING - December 2, 2025 - Imvax is moving its autologous glioblastoma immunotherapy IGV-001 toward the FDA, despite a missed primary endpoint in Phase IIb, betting that a six-month overall survival benefit and a novel "synergistic" treatment concept will resonate in a setting where outcomes have barely budged in two decades.

Phase IIb data highlight survival benefit despite PFS miss

In a mid-stage trial of 99 patients with newly diagnosed glioblastoma, Imvax evaluated IGV-001, a biologic-device combination, against placebo. While the study did not achieve its primary endpoint of improving progression-free survival, the company reported a median overall survival of 20.3 months in the treatment arm-around six months longer than in the control group.

SHERIDAN, WYOMING - December 2, 2025 - After years of volatility in Alzheimer's R&D, Roche's re-emergence with positive early data for trontinemab is reshaping expectations for the next competitive cycle in disease-modifying therapies, signaling that big pharma is not done pushing for better outcomes in this high-risk, high-need market.

From Aduhelm's fallout to a more mature Alzheimer's market

The modern Alzheimer's era was defined-some would say scarred-by the 2021 approval of Biogen and Eisai's Aduhelm, a controversial and costly monoclonal antibody that ultimately failed to deliver convincing clinical benefit and was later withdrawn. The backlash damaged Biogen's reputation and, for a time, cast doubt on the entire amyloid-directed approach, raising questions about regulatory standards and payer willingness to back expensive, marginally effective therapies.

SHERIDAN, WYOMING - December 2, 2025 - A series of FDA findings at Novo Nordisk's Bloomington, Indiana, fill/finish facility is forcing biotechs to rethink their commercial manufacturing strategies, with Regeneron and Scholar Rock now accelerating alternative capacity plans to break regulatory logjams linked to the ex-Catalent site.

FDA scrutiny at Novo's Bloomington site triggers CRLs

The Bloomington plant, one of three former Catalent sites Novo acquired for $11 billion to support surging GLP-1 demand, has become a bottleneck rather than a release valve for some of its biopharma customers. As a CDMO hub, the facility provided fill/finish services for a range of partners, but repeated quality issues have resulted in an Official Action Indicated (OAI) classification and multiple complete response letters (CRLs) from the FDA.

SHERIDAN, WYOMING - December 2, 2025 - As bispecifics, antibody-drug conjugates (ADCs), protein degraders and AI-designed mini-proteins move rapidly into clinical development, discovery teams are confronting a new bottleneck: not target ideas, but the practical engineering and scalable production of molecules that strain conventional biologics workflows.

From monoclonals to a radically more complex biologics toolbox

Monoclonal antibodies still anchor the biologics market, with more than 160 FDA approvals and a dominant share of global drug revenues. But the modality mix is shifting fast. More than 200 ADCs are now in clinical stages, bispecific approvals have climbed to 19 with sales above $12 billion in 2024, and regulators are increasingly supportive of novel protein formats.

SHERIDAN, WYOMING - December 2, 2025 - Microbial fermentation is moving back to the center of biologics manufacturing strategy, and contract development and manufacturing organizations (CDMOs) like AGC Biologics are under pressure to turn the platform's greatest strength-speed-into a reproducible, industrial-scale advantage.

Microbial fermentation's resurgence - and its speed problem

Microbial systems have long been valued for fast, efficient production of biologics, and they are now seeing renewed interest for a new generation of therapies. Yet the same speed that makes microbial fermentation attractive also makes it unforgiving. Typical production runs last around 48 hours, leaving very little time to diagnose and correct process deviations once a run is underway.

SHERIDAN, WYOMING - December 2, 2025 - As several large pharmas pull back from cell therapy, a core group of biopharma players is doubling down on CAR T and next-generation approaches, positioning themselves to capture long-term value in oncology and autoimmune disease even as near-term sentiment cools.

Big pharma exits reshape expectations, not potential

Over the past year, the cell therapy field has seen a string of high-profile retreats. Takeda halted new investments in the modality and is offloading its pipeline and platforms after more than eight years of heavy spending. Novo Nordisk followed by terminating all cell therapy work, including a type 1 diabetes program, with nearly 250 roles cut. Belgian biotech Galapagos also shut down its cell therapy business after failing to find a buyer.

SHERIDAN, WYOMING - December 2, 2025 - A wave of first-in-class hereditary angioedema (HAE) therapies is reshaping the U.S. Biotech & Research landscape, but questions remain over how quickly clinicians and patients will adopt these options in an already well-served rare disease market.

New approvals expand hereditary angioedema treatment choices

The HAE pipeline has accelerated dramatically, moving from basic C1 esterase inhibitors to sophisticated RNA-targeting and gene-editing approaches. The disease's life-threatening swelling attacks, including airway involvement, have long justified investment in both acute and prophylactic care, with the first FDA-approved preventive and on-demand therapies arriving in 2008 and 2009.

SHERIDAN, WYOMING - December 2, 2025 - As the United States grapples with record-setting government shutdowns and budget fights, the country's biotech and research ecosystem is confronting a deeper structural problem: federal science funding is increasingly unstable, putting early-stage innovation, talent pipelines and long-term competitiveness at risk. For an industry built on long horizons and high-risk discovery, interruptions to programs such as NIH grants and Small Business Innovation Research (SBIR) contracts are more than a temporary setback-they threaten the foundations of America's leadership in biopharma innovation.

Federal science funding as the backbone of U.S. biopharma

SHERIDAN, WYOMING - December 2, 2025 - As consumer packaged goods companies head into 2026, Kellanova sees technology not as a back-office enabler but as a growth catalyst connecting insight to action, purpose to performance, and innovation to impact. From agentic AI to connected commerce and smart, sustainable supply chains, the company's leadership argues that digital transformation in CPG is now about reinvention, not just modernization.

Agentic AI moves from pilots to real business impact

Agentic AI is emerging as a force multiplier across the CPG value chain, capable of analyzing real-time data, making recommendations and executing actions without constant human intervention. In practice, that means automating repetitive tasks, streamlining cross-functional workflows and reacting to market shifts with new speed and precision.

SHERIDAN, WYOMING - December 2, 2025 - With energy prices volatile and brand owners under pressure to cut carbon and costs, Sidel's EvoBLOW Laser technology is emerging as a strategic lever for beverage, food, home and personal care producers looking to modernize PET blowing operations. Following its breakthrough launch at drinktec and one year of industrial use in the field, President & CEO Pietro Cassani is outlining how the system's performance, simplicity and lightweighting potential are reshaping expectations for next-generation blowing equipment.

Laser-based blowing targets efficiency and TCO head-on

For producers operating high-speed PET lines, the shift from traditional halogen to laser-based blowing is more than a technical upgrade. It directly affects line efficiency, energy consumption and total cost of ownership across increasingly complex packaging portfolios.

SHERIDAN, WYOMING - December 2, 2025 - As regulatory expectations and investor scrutiny rise across Europe, the EUPD Group's ESG Transparency Award 2025 is spotlighting companies that no longer treat sustainability reporting as a mere compliance exercise, but as an engine for competitive differentiation and stakeholder trust. Presented in Bonn as part of this year's ESG Summit, the award recognizes more than 50 leading European companies that have embedded forward-looking ESG strategies into their organizations and communicate them transparently through robust sustainability reports.

ESG transparency moves from obligation to value driver

SHERIDAN, WYOMING - November 28, 2025 - Design studio molo is reimagining ambient lighting as both a material and a wellbeing tool, using paper-like textile lamps and sculptural luminaires to soften workspaces, public interiors and homes while improving acoustics and visual comfort.

Light as a Material for Architecture and Wellbeing

At molo, light is treated as a material in its own right, on par with wood or paper. With its ability to influence how people experience space, both natural and artificial light are central to the studio's approach. Textile lamps become architectural elements that modulate shadow, texture and colour, turning illumination into an emotional component of interior design rather than a purely functional afterthought.

SHERIDAN, WYOMING - November 28, 2025 - Fronius is expanding its renewable energy portfolio with the new Verto inverter family, positioning Verto and the hybrid Verto Plus as highly flexible solutions for agricultural businesses, commercial sites and single- and multi-family homes that need robust, future-proof PV system design and reliable backup power.

Flexible PV Design for Complex Rooftops and Mixed Module Layouts

At the core of the launch is the Fronius Verto, a high-performance inverter designed to cope with real-world installation challenges. Whether installers are working on complex roof structures, combining different module orientations or integrating various module types, the Verto is engineered to maintain efficiency and stability.

This flexibility allows EPCs and installers to:

SHERIDAN, WYOMING - November 28, 2025 - Hyundai Auto Canada has appointed long-time executive Ken Maisonville as chief operating officer (COO), reinforcing its focus on operational excellence and customer experience as the brand navigates intense competition, electrification and shifting consumer expectations in the Canadian automotive market.

New COO Role Unifies Sales, Marketing and Aftersales

In his newly created role, Maisonville will oversee Sales, Marketing and Aftersales, bringing these core commercial functions under a single leadership umbrella. The move is designed to accelerate decision-making and align strategies across the full customer journey, from brand awareness and lead generation to purchase, ownership and long-term retention.

SHERIDAN, WYOMING - November 28, 2025 - Growing demand for lightweight, design-driven and performance-oriented components is steadily expanding the global automotive alloy wheel market, with new research from Valuates Reports projecting revenues to rise from USD 11.4 billion in 2022 to USD 14.17 billion by 2029, a compound annual growth rate (CAGR) of 3.1% driven by OEM integration and aftermarket upgrades worldwide.

OEM Shift to Lightweight Wheels Reshapes Automotive & Mobility Strategies

In the global Automotive & Mobility industry, alloy wheels have moved from optional upgrade to core specification as manufacturers seek every opportunity to reduce vehicle weight and improve driving dynamics. Lower unsprung mass translates into smoother acceleration, more responsive steering and more efficient braking - all critical attributes as automakers balance efficiency, comfort and safety.